Clinical Trial Update: UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors [Phase 1]

View source ↗

Summary

Phase I, genotype-guided irinotecan study in a VIT regimen for pediatric relapsed/refractory solid tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Irinotecan (Irinotecan)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Pediatric Solid Tumor | Phase 1 | Status: RECRUITING